Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LIXT 
Lixte Biotechnology Holdings Inc (LIXT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LIXT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.37% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.97M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.37 | 52 Weeks Range 0.64 - 3.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.64 - 3.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.14% | Return on Equity (TTM) -155.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4085448 | Price to Sales(TTM) - |
Enterprise Value 4085448 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.5 | Shares Outstanding 2756990 | Shares Floating 2527941 |
Shares Outstanding 2756990 | Shares Floating 2527941 | ||
Percent Insiders 18.43 | Percent Institutions 15.84 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lixte Biotechnology Holdings Inc
Company Overview
History and Background
Lixte Biotechnology Holdings Inc. was founded in 2005. It focuses on developing drugs to treat human cancers and other diseases. The company's primary focus is on its lead clinical compound, LB-100, a protein phosphatase inhibitor.
Core Business Areas
- Drug Development: Lixte's core business revolves around the development and commercialization of novel therapies, particularly LB-100, for various cancer types and other diseases.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Development: Lixte invests in R&D to discover and develop new drug candidates and improve existing therapies.
Leadership and Structure
Dr. John S. Kovach is the CEO and Founder. The company has a relatively small organizational structure focused on research and development.
Top Products and Market Share
Key Offerings
- LB-100: LB-100 is Lixte's lead clinical compound, a protein phosphatase inhibitor being developed for various cancer indications. Market share data is not readily available as it is still in clinical development. Potential competitors include companies developing similar phosphatase inhibitors or therapies for the same cancer indications. Exact revenue data is not available.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and characterized by rapid technological advancements. It involves developing and commercializing new therapies for various diseases.
Positioning
Lixte is a small-cap biotechnology company focused on a niche area of cancer therapy. Its competitive advantage lies in its novel protein phosphatase inhibitor, LB-100.
Total Addressable Market (TAM)
The TAM for cancer therapies is substantial, estimated to be hundreds of billions of dollars annually. Lixte, being a small-cap company, aims to capture a portion of this market with LB-100, which is still in development. Its TAM depends on which cancer indications the drug is ultimately approved for.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (LB-100)
- Experienced leadership team
- Potential for targeting multiple cancer types
- Promising preclinical and clinical data
Weaknesses
- Limited financial resources
- Reliance on a single drug candidate
- High risk of clinical trial failure
- Limited commercialization capabilities
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Potential for orphan drug designation
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- TAK
Competitive Landscape
Lixte faces competition from larger, more established pharmaceutical companies. Its advantage lies in its novel approach and potential for targeting specific cancer pathways. Lixte's survival depends on future strategic planning.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on research and development.
Future Projections: Future growth depends on the successful development and commercialization of LB-100. Analyst estimates are highly speculative.
Recent Initiatives: Recent initiatives include advancing LB-100 through clinical trials and exploring potential partnerships.
Summary
Lixte Biotechnology is a high-risk, high-reward small-cap company. Its success is heavily dependent on the clinical trial results of its lead drug candidate, LB-100. While the drug shows promise, the company faces financial constraints and stiff competition. The company needs to secure partnerships and funding to advance its pipeline or else it has a limited survival time.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lixte Biotechnology Holdings Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2007-09-21 | CEO & Chairman Mr. Geordan G. Pursglove | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://lixte.com |
Full time employees 2 | Website https://lixte.com | ||
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.